WO2004058265A1 - Bibliotheques de composes de derives de pyrazine 2,3-substitues pouvant se fixer aux recepteurs couples a la proteine g - Google Patents
Bibliotheques de composes de derives de pyrazine 2,3-substitues pouvant se fixer aux recepteurs couples a la proteine g Download PDFInfo
- Publication number
- WO2004058265A1 WO2004058265A1 PCT/GB2003/005668 GB0305668W WO2004058265A1 WO 2004058265 A1 WO2004058265 A1 WO 2004058265A1 GB 0305668 W GB0305668 W GB 0305668W WO 2004058265 A1 WO2004058265 A1 WO 2004058265A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- list
- compounds
- formula
- attachment
- point
- Prior art date
Links
- 0 CS(Nc1nccnc1-c1ccc(CN(*)*)cc1)(=O)=O Chemical compound CS(Nc1nccnc1-c1ccc(CN(*)*)cc1)(=O)=O 0.000 description 17
- YCOLGRLQJGCUFT-UHFFFAOYSA-N CNc(cc1)cc(C(N2C)=O)c1C2=O Chemical compound CNc(cc1)cc(C(N2C)=O)c1C2=O YCOLGRLQJGCUFT-UHFFFAOYSA-N 0.000 description 1
- JUPQGBQCAWXFLZ-UHFFFAOYSA-N O=S(c(cc1)ccc1Cl)(Nc1nccnc1-c1ccc(CCl)cc1)=O Chemical compound O=S(c(cc1)ccc1Cl)(Nc1nccnc1-c1ccc(CCl)cc1)=O JUPQGBQCAWXFLZ-UHFFFAOYSA-N 0.000 description 1
- GIWOBAVZJSMBQT-UHFFFAOYSA-N OCc(cc1)ccc1-c1nccnc1NS(c(cc1)ccc1Cl)(=O)=O Chemical compound OCc(cc1)ccc1-c1nccnc1NS(c(cc1)ccc1Cl)(=O)=O GIWOBAVZJSMBQT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
Definitions
- the present invention relates to compounds capable of binding to G-protein coupled receptors.
- a library of compounds is provided for use in screening 10 programmes against GPCR targets as well as the individual compounds for use in hit to lead and lead optimisation projects and similar stages in the drug discovery process.
- the method also provides methods for making compounds and 15 libraries.
- Screening libraries are commonly collections of compounds from several sources. As a result, they typically contain compounds synthesised as a part of previous projects in the history of a company. With regard to drug discovery, these collections will be drug-like but are likely to be limited in scope and will be directed to certain areas of a particular project. It has been the common practice of many pharmaceutical companies in recent times to augment the collections by purchasing either single compounds from vendors or by contracting the synthesis of combinatorial libraries of compounds. The singly purchased compounds may have been selected to fill in areas of compound space poorly represented in the compound collections. Combinatorial libraries are typically synthesised around well-performing chemistries with some ' design based on producing ⁇ diversity' in compound space.
- a complementary approach, and one that is increasingly preferred, is to screen focused libraries against the target of choice. Focused libraries are becoming of increasing importance in their ability to generate hits capable of rapid expansion in many areas including GPCRs . Such libraries are slightly more expensive to prepare but have attributes of reliability, reproducibility and provide a considerably higher hit rate: typically 10-100 fold and above compared with random screening. They are, however, very difficult to design and their efficiency relates directly to the amount of effort that has gone into the design. Using focused libraries, it is usually possible to get a number of hits in the low micromolar and below range. As there is a defined set of compounds there is the potential to observe indications of SAR in a chemical series and progress the chemistry efficiently.
- GPCRs G-protein-coupled receptors
- the rhodopsin receptor is somewhat unusual in its interactions with its ligand and is not used as a drug target. Nevertheless the overall three dimensional arrangement can be deduced from the X-ray and is in accordance with previous work based upon bacteriorhodopsin receptor which is not G-protein-coupled.
- GPCRs are most often characterised by sequence homology as being comprised of several sub-families. Most attention currently is directed towards Family A receptors as being the most tractable class historically and also the one with the most potential targets.
- Family A comprises about 300 receptors that are potential drug targets, approximately half of which have known ligands and the rest, the so-called orphan receptors.
- the group of druggable receptors is composed essentially of two types: those whose natural ligand interacts wholly within the transmembrane domain, such as the aminergic, nucleotide-like, prostaglandin receptors, etc. and those peptide liganded receptors, which have a large part of their interactions in the extracellular region and which may insert a peptide loop or tail into the transmembrane region to effect signal transduction. Examples of this class are angiotensin, cholecystokinin and opioid receptors.
- the focused library provided herein is designed to interact with a range of the family A receptors.
- Each library is a defined set of compounds that will enhance the probability of finding a small molecule that will interact with one or more type of GPCR receptor.
- focused libraries can be provided having compounds which will interact with aminergic GPCRs, and peptidic GPCRs requiring an obligatory positive charge in ligands, or other types or groups of GPCRs.
- Focused libraries according to this invention can provide hit rates of 1-13% or more for the requisite predicted GPCRs from both amine- and peptide-liganded classes and with agonists and antagonists.
- library means a group of compounds which are structurally related by virtue of a core chemical structure (or “scaffold”) but which differ from each other by virtue of permutation of specific substituent groups attached to the scaffold.
- such a library will consist of or comprise a number of compounds, e.g. as many as about 100, 1000,2000, 3000 or indeed 10,000 compounds.
- the number of compounds should be sufficient to provide an adequate diversity of related compounds without being so large as to be unduly complex/expensive to produce.
- the substituent may appear in the compound exactly as shown (i.e. simply covalently bonded to the scaffold) or may be a derivative of the shown chemical formula of the substituent by virtue of use of a reactive group to couple the substituent to the scaffold.
- the total number of permutations created by the permitted substituents may be a very large number, far greater in magnitude than the actual number of compounds in an actual library.
- the number of possible compounds for any "virtual" library may well greatly exceed the number of synthesised compounds making up an embodiment of the "real” library.
- the invention is intended to encompass libraries having all, and a number, which is less than all, of the permitted substitutions represented by compounds therein.
- WO 03/00308 discloses a compound library suitable for use in identifying compounds which act on G-protein coupled receptors, also called 7TM receptors. This compound library may overlap with WO 03/00308, but is not identical to the compound library of the present invention. Where compounds per se are claimed by the present ' invention, generally any compounds specifically claimed in WO 03/00308 are hereby disclaimed per se.
- Library 5 is designed to pick up interactions with receptors for a subset of peptidic receptors, especially those with recognition sites for amide and acidic ligands based around TM3 and TM6.
- This group is represented by such receptors as Bombesin (BSR3) , Endothelin A, Neuromedin U and Neuropeptide Y amongst others.
- BSR3 Bombesin
- Endothelin A Endothelin A
- Neuromedin U and Neuropeptide Y amongst others.
- the presence of the amide-acid recognition site here is a consequence of the requirements for binding the natural ligands either with C-terminal regions or with the backbone of peptide loops .
- the techniques used in designing this library have also provided the opportunity to design both agonists and antagonists for these receptors .
- the invention provides a compound library comprising of a set of structurally related compounds of the following general formulae:
- 3-chloroprazine-2-carbonitrile (1.39g (0.01 mol)) and 4- hydroxymethyl phenyl boronic acid (1.5g, 0.011 mol) were dissolved in dimethoxyethane (30ml) and potassium carbonate (3.8g) in water (15ml) added.
- Triphenyl phosphine (0.39g) and Palladium (II) acetate 1(0. llg) were added and the mixture was stirred and heated to 90°C overnight, after cooling the reaction was diluted with ethyl acetate (30ml) , filtered through celite and the organic layer separated, dried and evaporated.
- the reaction was cooled, added to water (800ml) and washed with ethyl acetate (2x250ml) .
- the aqueous phase was acidified with citric acid and extracted with ethyl acetate (3x500ml) .
- the organic extracts were combined, washed with brine (100ml) , dried over MgS0 and evaporated down.
- Cyclopropane sulphonic acid (3-chloro pyrazin-2-yl) amide (2.42g, 0.008mmol) and 4-formyl benzene boronic acid (1.4g, 0.0093 mol) were dissolved in dimethoxy ethane (30ml) and potassium carbonate (3.2g in 15ml water) added.
- Triphenyl phosphine (0.32g) and palladium (II) acetate (93mg) were added and the mixture stirred at 90°C overnight. The mixture was cooled and diluted with diethyl ether (60ml) . Water (50ml) was added and the cloudy solution was filtered through celite.
- reaction was added to water (200ml) , acidified with AcOH (3ml) and extracted with ethyl acetate (4x50ml) .
- the organic phases were combined, washed with water (2x100ml) , dried over magnesium sulphate and evaporated down.
- Benzyl sulphonyl chloride 38mg, 0.2 mmol
- Hunigs Base lml, 1.0M in dimethyl formamide 1.0 mmol
- the aqueous phase was acidified with acetic acid (1.25ml) and extracted with ethyl acetate (2x40ml) .
- the organic phases were combined, washed with water (40ml) , dried over magnesium sulphate and evaporated under reduced pressure.
- the product was purified by flash chromatography using 30% ethyl acetate in petrol to give 165mg of 4-Chloro-N-phenyl-3, 4, 5, 6- tetrahydro-2H- [1,2' ] bipyazinyl-3' -yl) benzenesulphonamide .
- the Gilson 215 was used as both auto-sampler and fraction collector.
- the gradient used was 95% water / 5% acetonitrile (each containing 0.1% formic acid) for 1.5 min to 95% acetonitrile over 6 min then held at 95% acetonitrile for 3.0 min.
- the solvent mixture was then returned to the initial conditions over 0.25 min.
- the column was re- equilibrated over 2.5 minutes prior to the next injection.
- the purification was controlled by Unipoint software, triggering a threshold collection value monitoring at 240 nm. Collected fractions were analysed by LCMS . The fractions that contained the desired product were concentrated by vacuum centrifugation and the resultant residue dried by freeze-drying.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Structural Engineering (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2003/005668 WO2004058265A1 (fr) | 2002-12-24 | 2003-12-24 | Bibliotheques de composes de derives de pyrazine 2,3-substitues pouvant se fixer aux recepteurs couples a la proteine g |
AU2003290346A AU2003290346A1 (en) | 2002-12-24 | 2003-12-24 | Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0230195A GB0230195D0 (en) | 2002-12-24 | 2002-12-24 | Compound Libraries |
GB0230195.0 | 2002-12-24 | ||
PCT/GB2003/005668 WO2004058265A1 (fr) | 2002-12-24 | 2003-12-24 | Bibliotheques de composes de derives de pyrazine 2,3-substitues pouvant se fixer aux recepteurs couples a la proteine g |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004058265A1 true WO2004058265A1 (fr) | 2004-07-15 |
Family
ID=41328881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/005668 WO2004058265A1 (fr) | 2002-12-24 | 2003-12-24 | Bibliotheques de composes de derives de pyrazine 2,3-substitues pouvant se fixer aux recepteurs couples a la proteine g |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003290346A1 (fr) |
WO (1) | WO2004058265A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089905A1 (fr) * | 2003-04-14 | 2004-10-21 | Abbott Gmbh & Co. Kg | Composes n-[(piperazinyl)hetaryl]arylsulfonamide dotes d'une affinite pour le recepteur de la dopamine d3 |
WO2006111560A2 (fr) * | 2005-04-21 | 2006-10-26 | Laboratoires Serono S.A. | Pyrazine sulfonamides 2,3 substituees |
EP1838674A2 (fr) * | 2005-01-14 | 2007-10-03 | ChemoCentryx Inc | Sulfonamides d'heteroaryle et ccr2 |
US7320979B2 (en) | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
WO2009147990A1 (fr) * | 2008-06-02 | 2009-12-10 | 萬有製薬株式会社 | Nouveau dérivé d'isoxazole |
WO2012052420A1 (fr) | 2010-10-20 | 2012-04-26 | Merck Serono S.A. Geneva | Procédé de préparation de n-(3-amino-quinoxalin-2-yl)-sulfonamides substitués et de leurs n-(3-chloro-quinoxalin-2-yl)sulfonamides intermédiaires |
US8546408B2 (en) | 2007-07-12 | 2013-10-01 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation |
CN106831556A (zh) * | 2015-12-07 | 2017-06-13 | 成都海创药业有限公司 | 磺酰胺类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途 |
US10206912B2 (en) | 2006-07-14 | 2019-02-19 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
US10758540B2 (en) | 2017-10-11 | 2020-09-01 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
US10973809B2 (en) | 2016-11-23 | 2021-04-13 | Chemocentryx, Inc. | Method of treating focal segmental glomerulosclerosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003424A1 (fr) * | 1994-07-26 | 1996-02-08 | The Scripps Research Institute | Bibliotheques combinatoires de molecules et procedes de production des memes |
WO1998054116A1 (fr) * | 1997-05-28 | 1998-12-03 | Cadus Pharmaceutical Corporation | Synthese et utilisation de composes heteroaromatiques a base de thiophene et de pyrrole |
WO2003003008A1 (fr) * | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Bibliotheques chimiques utiles aux procedes de decouvertes de medicaments |
WO2003031406A2 (fr) * | 2001-10-12 | 2003-04-17 | Irm Llc | Squelettes d'inhibiteurs de kinase et leurs methodes de preparation |
WO2003066629A2 (fr) * | 2002-02-06 | 2003-08-14 | Vertex Pharmaceuticals Incorporated | Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3 |
-
2003
- 2003-12-24 AU AU2003290346A patent/AU2003290346A1/en not_active Abandoned
- 2003-12-24 WO PCT/GB2003/005668 patent/WO2004058265A1/fr not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003424A1 (fr) * | 1994-07-26 | 1996-02-08 | The Scripps Research Institute | Bibliotheques combinatoires de molecules et procedes de production des memes |
WO1998054116A1 (fr) * | 1997-05-28 | 1998-12-03 | Cadus Pharmaceutical Corporation | Synthese et utilisation de composes heteroaromatiques a base de thiophene et de pyrrole |
WO2003003008A1 (fr) * | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Bibliotheques chimiques utiles aux procedes de decouvertes de medicaments |
WO2003031406A2 (fr) * | 2001-10-12 | 2003-04-17 | Irm Llc | Squelettes d'inhibiteurs de kinase et leurs methodes de preparation |
WO2003066629A2 (fr) * | 2002-02-06 | 2003-08-14 | Vertex Pharmaceuticals Incorporated | Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3 |
Non-Patent Citations (2)
Title |
---|
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PALAMIDASSI, G.: "Pyrazine derivatives. VI", XP002277788, retrieved from STN Database accession no. 59:75305 * |
FARMACO, EDIZIONE SCIENTIFICA (1963), 18(8), 557-65 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7320979B2 (en) | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
US8476275B2 (en) * | 2003-04-14 | 2013-07-02 | Abbott Gmbh & Co. Kg | N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor |
WO2004089905A1 (fr) * | 2003-04-14 | 2004-10-21 | Abbott Gmbh & Co. Kg | Composes n-[(piperazinyl)hetaryl]arylsulfonamide dotes d'une affinite pour le recepteur de la dopamine d3 |
EP2354126A1 (fr) * | 2005-01-14 | 2011-08-10 | ChemoCentryx, Inc. | Sulfonamides d'hétéroarylamide et CCR2 |
EP1838674A2 (fr) * | 2005-01-14 | 2007-10-03 | ChemoCentryx Inc | Sulfonamides d'heteroaryle et ccr2 |
JP2008526996A (ja) * | 2005-01-14 | 2008-07-24 | ケモセントリックス, インコーポレイテッド | ヘテロアリールスルホンアミドおよびccr2 |
EP1838674A4 (fr) * | 2005-01-14 | 2010-01-06 | Chemocentryx Inc | Sulfonamides d'heteroaryle et ccr2 |
EP2474532A1 (fr) * | 2005-01-14 | 2012-07-11 | ChemoCentryx, Inc. | Sulfonamides d'hétéroaryle et CCR2 |
JP2008536892A (ja) * | 2005-04-21 | 2008-09-11 | ラボラトワール セローノ ソシエテ アノニム | 2,3置換ピラジンスルホンアミド |
WO2006111560A3 (fr) * | 2005-04-21 | 2007-05-03 | Applied Research Systems | Pyrazine sulfonamides 2,3 substituees |
AU2006237365B2 (en) * | 2005-04-21 | 2012-09-20 | Merck Serono Sa | 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2 |
US8796280B2 (en) | 2005-04-21 | 2014-08-05 | Merck Serono, S.A. | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors |
WO2006111560A2 (fr) * | 2005-04-21 | 2006-10-26 | Laboratoires Serono S.A. | Pyrazine sulfonamides 2,3 substituees |
US10206912B2 (en) | 2006-07-14 | 2019-02-19 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
US10532044B2 (en) | 2006-07-14 | 2020-01-14 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
US11433061B2 (en) | 2006-07-14 | 2022-09-06 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
US10899765B2 (en) | 2007-07-12 | 2021-01-26 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation |
US8546408B2 (en) | 2007-07-12 | 2013-10-01 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation |
US9394307B2 (en) | 2007-07-12 | 2016-07-19 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation |
US9745312B2 (en) | 2007-07-12 | 2017-08-29 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation |
US10208050B2 (en) | 2007-07-12 | 2019-02-19 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation |
JPWO2009147990A1 (ja) * | 2008-06-02 | 2011-10-27 | Msd株式会社 | 新規イソオキサゾール誘導体 |
WO2009147990A1 (fr) * | 2008-06-02 | 2009-12-10 | 萬有製薬株式会社 | Nouveau dérivé d'isoxazole |
WO2012052420A1 (fr) | 2010-10-20 | 2012-04-26 | Merck Serono S.A. Geneva | Procédé de préparation de n-(3-amino-quinoxalin-2-yl)-sulfonamides substitués et de leurs n-(3-chloro-quinoxalin-2-yl)sulfonamides intermédiaires |
CN106831556A (zh) * | 2015-12-07 | 2017-06-13 | 成都海创药业有限公司 | 磺酰胺类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途 |
CN106831556B (zh) * | 2015-12-07 | 2020-09-01 | 成都海创药业有限公司 | 磺酰胺类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途 |
US10973809B2 (en) | 2016-11-23 | 2021-04-13 | Chemocentryx, Inc. | Method of treating focal segmental glomerulosclerosis |
US11324736B2 (en) | 2016-11-23 | 2022-05-10 | Chemocentryx, Inc. | Method of Treating Focal Segmental Glomerulosclerosis |
US11382915B2 (en) | 2017-10-11 | 2022-07-12 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
US10758540B2 (en) | 2017-10-11 | 2020-09-01 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
Also Published As
Publication number | Publication date |
---|---|
AU2003290346A1 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004058265A1 (fr) | Bibliotheques de composes de derives de pyrazine 2,3-substitues pouvant se fixer aux recepteurs couples a la proteine g | |
CA2440559C (fr) | Nouveaux composes non imidazole | |
EP1436272B1 (fr) | Derives d'amide biphenylcarboxilique utilises comme inhibiteurs de la kinase p38 | |
JP2015506923A (ja) | RORcモジュレーターとしてのベンジルスルホンアミド誘導体 | |
EP1440052A1 (fr) | Derives de benzamide utilises comme antagonistes des recepteurs de l'orexine | |
HU227543B1 (en) | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them | |
EP3272741A1 (fr) | Nouvelles formes cristallines de solvate stable d'eluxadoline | |
JP2005519038A (ja) | エチレンジアミン誘導体およびそのオレキシン−受容体アンタゴニストとしての使用 | |
TW200812945A (en) | Method for making sulfonic acid ester | |
Renteria-Gomez et al. | Synthesis of azepino [4, 5-b] indol-4-ones via MCR/free radical cyclization and in vitro–in silico studies as 5-Ht6R ligands | |
Nagaraju et al. | Synthesis of functionalized isoxazole–oxindole hybrids via on water, catalyst free vinylogous Henry and 1, 6-Michael addition reactions | |
JP2004517042A (ja) | オレフィン置換芳香族または複素芳香族の製造方法 | |
CN110283082A (zh) | 一种3-苯基丙胺的制备方法 | |
CN106187897B (zh) | 一种稠环吡唑类化合物的合成方法 | |
WO2004111056A2 (fr) | Banques de composes | |
CN108484509B (zh) | 一类带有Boc氨基巴比妥酸-环己二烯螺环化合物及其合成方法 | |
WO2004058755A2 (fr) | Bibliotheques de composes | |
CN107721919B (zh) | 苯基喹啉类trpv1拮抗剂及其制备方法和应用 | |
WO2004058720A2 (fr) | Banques de composes | |
WO2005023794A2 (fr) | Banques de composes | |
WO2004058259A1 (fr) | Banque de composes contenant des derives de n-(aminocarbonyl)-piperidine-4-carboxamide, capables de se fixer aux recepteurs couples a la proteine g | |
CN107709318A (zh) | 食欲素受体拮抗剂化合物的晶型及其制备方法和应用 | |
US20100076197A1 (en) | Process for rimonabant | |
CN114349703B (zh) | 一种三氟甲基-4-氰基吡唑类化合物、其制备方法及应用 | |
HU228918B1 (en) | Method for crystallising n-(4-trifluoromethylphenyl)-5-methyl-isoxazole-4-carboxamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 06.10.2005) |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |